Autoimmune disease Archives

News and Trends 1 Nov 2017

Belgian Biotech Launches IPO, Readying Itself to Fight Multiple Sclerosis

Apitope develops highly specific peptide therapeutics for multiple sclerosis and other autoimmune diseases, and will now launch an IPO on Brussels Euronext. Apitope hopes to treat a number of autoimmune diseases affecting many systems throughout the body. The company has developed peptides, ‘apitopes‘, that tackle the immunological basis of the disease. The company has just […]

November 1, 2017 - 2 minutesmins - By Alex Dale

Interview 28 Sep 2017

What are Alphabodies and How Do They Drug the Undruggable?

Philip found out more about a new form of protein therapeutics being developed by Complix, which aims to drug the undruggable. Mark Vaeck, Co-Founder and CEO of Complix, has over 25 years experience in the biotech and pharma industries. His latest company Complix, a Belgian immuno-oncology biotech, is developing Alphabodies, tiny therapeutic proteins that can […]

September 28, 2017 - 3 minutesmins - By Alex Dale

News and Trends 15 Sep 2017

Swiss-US Partners Reveal New Candidate for Autoimmune Disease

Numab and Intarcia have a first candidate to combine a tri-specific antibody fragment with a mini-osmotic pump delivery system to fight autoimmune disease. Numab and Intarcia partnered in 2015 to develop a new form of treatment for diabetes, obesity and autoimmune diseases. After initial research, the team has now selected its first candidate for clinical […]

September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Eli Lilly Topas Therapeutics Autoimmune Disease

News and Trends 22 Aug 2017

Eli Lilly Partners with German Biotech Against Autoimmune Disease

Topas Therapeutics has signed a multi-year agreement with Eli Lilly to develop drug candidates for antigen-specific immunotherapy. The young Topas Therapeutics, a spin off from Evotec launched just last year, has managed to sign a research collaboration deal with big pharma Eli Lilly. The partners will work together on selecting external antigens that induce inflammation and autoimmune disease […]

August 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Jul 2017

German Biotech Strikes License Deal with Japanese Dermatology Firm

4SC has granted an exclusive worldwide license to the Japanese dermatology firm Maruho on a class of compounds against the Kv1.3 ion channel. Under the agreement, 4SC could receive up to €105M in upfront and milestone payments plus royalties on future sales. The deal is part of the German company’s strategy to out license non-core […]

July 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 5 Jul 2017

Galapagos and Gilead Launch the Fifth New Trial for Filgotinib this Year

With the addition of uveitis, Galapagos and Gilead are raising to 10 the number of indications in filgotinib’s clinical pipeline. Galapagos and Gilead clearly have big expectations for filgotinib. The small molecule is already in Phase III for rheumatoid arthritis, Crohn’s disease and ulcerative colitis. The team is now launching a new Phase II trial in […]

July 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández

type 1 diabetes insulin therapy uppsala university hospital

News and Trends 23 Jun 2017

Diabetic Patients that Still Produce Insulin might be the Key to a New Therapy

A study from Uppsala University has identified higher levels of interleukin-35 in type 1 diabetics that still produce insulin years after their diagnosis. Researchers at Uppsala University have published the first study in humans that shows the potential of interleukin-35 (IL-35) as a promising new target to treat type 1 diabetes. The results, published in […]

June 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Ose Immunotherapeutics bpifrance milestone bowel disease

News and Trends 22 Jun 2017

Immunotherapy for Bowel Disease Gets €2.6M Milestone Payment from Bpifrance

OSE Immunotherapeutics has successfully completed the necessary milestones to bring a treatment for autoimmune disease to the clinic, triggering a milestone payment from its partner Bpifrance. OSE Immunotherapeutics, based in Nantes, France, has received €2.6M from the French public investment agency Bpifrance after completing another milestone in the development of a therapy for inflammatory bowel disease. […]

June 22, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 8 May 2017

Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis

Teva and Active Biotech have failed Phase III with their Multiple Sclerosis drug laquinimod to treat the relapsing-remitting form of the disease. Teva and Active Biotech have faced another setback with their long-expected successor to Teva’s Copaxone, laquinimod, for the treatment of Multiple Sclerosis (MS). The drug failed to meet the primary endpoint, trying to improve the […]

May 8, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 13 Mar 2017

This Dutch Company is Upgrading ADCs for Immunotherapy

T-Guard is CEO and co-founder Ypke van Oosterhout’s life work. He told us about the technology that he has been developing since his graduate studies. It was during his post-MSc research that Ypke van Oosterhout ‘discovered’ T-Guard, a technology which neutralizes rogue T cells. Seeing its clinical potential, Oosterhout took the concept and ran with it — […]

March 13, 2017 - 7 minutesmins - By External Contributor

News and Trends 9 Feb 2017

Alma Bio Therapeutics is Aiming to Revolutionize the Treatment of IBD

A new immune modulator to treat Inﬂammatory Bowel Diseases (IBD) is the lead asset in development at Alma Bio Therapeutics. We had the opportunity to meet up with the company’s co-founder and CEO, Binah Baum, to hear more about their fresh approach to treating IBD and other autoimmune diseases. Binah Baum, another female leader in […]

February 9, 2017 - 6 minutesmins - By External Contributor

Screenshot 2017 01 27 at 2.17.05 PM 1 e1485524200727

Startup Scout 27 Jan 2017

Needle-free Treatments for Autoimmune Disorders from Switzerland

It’s back to go back to the mainland. This week’s stop is in Hergiswill, a city by one of the many beautiful seas that can be found in Switzerland. There, the young biotech BioLingus is developing needle-free therapies for chronic diseases. City: Hergiswill, Switzerland Founded: 2014 Employees: 1-10 Financial data: N/A Mission: BioLingus develops non-invasive treatments for autoimmune and inflammatory […]

January 27, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Autoimmune disease

Belgian Biotech Launches IPO, Readying Itself to Fight Multiple Sclerosis

What are Alphabodies and How Do They Drug the Undruggable?

Swiss-US Partners Reveal New Candidate for Autoimmune Disease

Eli Lilly Partners with German Biotech Against Autoimmune Disease

German Biotech Strikes License Deal with Japanese Dermatology Firm

Galapagos and Gilead Launch the Fifth New Trial for Filgotinib this Year

Diabetic Patients that Still Produce Insulin might be the Key to a New Therapy

Immunotherapy for Bowel Disease Gets €2.6M Milestone Payment from Bpifrance

Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis

This Dutch Company is Upgrading ADCs for Immunotherapy

Alma Bio Therapeutics is Aiming to Revolutionize the Treatment of IBD

Needle-free Treatments for Autoimmune Disorders from Switzerland

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!